Detalles de la búsqueda
1.
Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes.
BMC Med
; 21(1): 234, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37400832
2.
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Lancet Oncol
; 21(7): 914-922, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32539942
3.
Role and targeting of anaplastic lymphoma kinase in cancer.
Mol Cancer
; 17(1): 30, 2018 02 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29455642
4.
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy.
Int J Mol Sci
; 19(11)2018 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-30441809
5.
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC.
J Thorac Oncol
; 2024 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38461929
6.
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
Clin Lung Cancer
; 25(2): 190-195, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38262770
7.
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible.
Crit Rev Oncol Hematol
; 182: 103899, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36596401
8.
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
Eur J Cancer
; 195: 113404, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37948842
9.
High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
Lung Cancer
; 186: 107417, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37918061
10.
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.
J Immunother Cancer
; 11(6)2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37286305
11.
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy.
Front Immunol
; 14: 1289434, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38304255
12.
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC.
Lung Cancer
; 174: 36-44, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36302311
13.
Chemotherapy-induced bowel ischemia: diagnostic imaging overview.
Abdom Radiol (NY)
; 47(5): 1556-1564, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33811514
14.
Immunotherapy for head and neck cancer: Present and future.
Crit Rev Oncol Hematol
; 174: 103679, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35395371
15.
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review.
Cancers (Basel)
; 14(23)2022 Nov 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36497292
16.
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.
J Exp Clin Cancer Res
; 41(1): 109, 2022 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35346313
17.
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC.
Front Immunol
; 13: 987639, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36203609
18.
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
Clin Lung Cancer
; 23(1): e17-e28, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34334296
19.
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
Eur J Cancer
; 177: 175-185, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36368251
20.
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients.
Front Oncol
; 12: 1078822, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36755856